Compare IDN & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDN | XBIT |
|---|---|---|
| Founded | 1994 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.5M | 66.8M |
| IPO Year | 2014 | 2015 |
| Metric | IDN | XBIT |
|---|---|---|
| Price | $2.41 | $2.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $7.33 | N/A |
| AVG Volume (30 Days) | ★ 297.2K | 43.6K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 220.00 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $4,433,454.00 | N/A |
| Revenue This Year | $12.54 | N/A |
| Revenue Next Year | $15.32 | N/A |
| P/E Ratio | $40.00 | ★ N/A |
| Revenue Growth | ★ 23.21 | N/A |
| 52 Week Low | $2.32 | $2.09 |
| 52 Week High | $9.08 | $3.44 |
| Indicator | IDN | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 31.57 | 40.04 |
| Support Level | N/A | N/A |
| Resistance Level | $3.00 | $2.48 |
| Average True Range (ATR) | 0.09 | 0.04 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 18.02 | 15.38 |
Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company includes solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.